Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Agency, append, Attorney, Cell, compensatory, Consent, contract, correct, correction, error, ID, Indemnification, KBS, PA, PCAOB, Philadelphia, recovery
Removed:
acquire, acquired, addition, additional, administration, applicable, applied, appointed, approval, approximately, assurance, based, board, clinical, close, Code, collectively, commercial, committee, compliance, composed, conjunction, connection, consideration, consist, corporate, corporation, covering, degree, designed, determined, development, direct, director, disclosure, drug, employee, established, evaluated, evaluating, exceed, exercisable, exercise, experience, extent, faculty, federal, finance, founder, fund, grant, hedge, highly, Hill, identification, include, including, incurred, industry, initial, interest, investment, issuable, John, key, knowledge, legal, life, limited, Loren, Madison, make, marketing, material, member, note, number, obligation, offering, operating, performance, performed, pharmaceutical, preparation, present, presented, President, principal, prior, publicly, range, read, recently, referred, related, rendered, requirement, research, responsibility, responsible, review, risk, scientific, SEC, sell, September, service, share, small, stage, statutory, Stefan, Stephen, stockholder, strategic, subsequent, subsequently, summary, table, tax, technology, therapeutic, time, traded, treatment, United, University, Wisconsin
Filing tables
Filing exhibits
CLRB similar filings
Filing view
External links
Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James V. Caruso, President and Chief Executive Officer, Cellectar Biosciences, Inc., certify that:
1. | I have reviewed this Annual Report on Form 10-K of Cellectar Biosciences, Inc.; and |
2. | Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
/s/ James V. Caruso | |
Date: March 16, 2023 | James V. Caruso |
President and Chief Executive Officer |